loading page

NKp30 -- a prospective target for new cancer immunotherapy strategies
  • Pedro Pinheiro,
  • Goncalo Justino,
  • M. Matilde Marques
Pedro Pinheiro
Universidade de Lisboa Instituto Superior Técnico
Author Profile
Goncalo Justino
Universidade de Lisboa Instituto Superior Técnico
Author Profile
M. Matilde Marques
Universidade de Lisboa Instituto Superior Técnico
Author Profile

Peer review status:ACCEPTED

06 Apr 2020Submitted to British Journal of Pharmacology
07 Apr 2020Submission Checks Completed
07 Apr 2020Assigned to Editor
07 Apr 2020Reviewer(s) Assigned
24 May 2020Editorial Decision: Revise Minor
21 Jun 20201st Revision Received
25 Jun 2020Submission Checks Completed
25 Jun 2020Assigned to Editor
26 Jun 2020Reviewer(s) Assigned
16 Jul 2020Review(s) Completed, Editorial Evaluation Pending
27 Jul 2020Editorial Decision: Accept

Abstract

NK cells are an important arm of the innate immune system, and they constitutively express the NKp30 receptor. NKp30-mediated responses are triggered by the binding of specific ligands, such as tumour cell-derived B7-H6, and involve the secretion of cytotoxic mediators TNF-α, IFN-γ, perforins and granzymes. The latter two constitute a target cell-directed response that is critical in the process of immunosurveillance. The structure of NKp30 is presented, focusing on the ligand-binding site, on the ligand-induced structural changes, and on the experimental data available correlating structure and binding affinity. The translation of NKp30 structural changes to disease progression is also reviewed. NKp30 role in immunotherapy has been explored in chimeric antigen receptor T-cell (CAR-T) therapy. However, antibodies or small ligands targeting NKp30 have not yet been developed. The data reviewed unveils the key structural aspects that must be considered for drug design in order to develop novel immunotherapy approaches.